Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

1. Siena, S.
2. Di Bartolomeo, M.
3. Raghav, K.
4. Masuishi, T.
5. Loupakis, F.
6. Kawakami, H.
7. Yamaguchi, K.
8. Nishina, T.
9. Fakih, M.
10. Elez, E.
11. Rodriguez, J.
12. Ciardiello, F.
13. Komatsu, Y.
14. Esaki, T.
15. Chung, K.
16. Wainberg, Z.
17. Sartore-Bianchi, A.
18. Saxena, K.
19. Yamamoto, E.
20. Bako, E.
21. Okuda, Y.
22. Shahidi, J.
23. Grothey, A.
24. Yoshino, T.